Exhibitors Tackle Disease Mechanisms

Learn about the latest developments in genetic and genomic testing in the ATS 2016 Exhibit Hall.

Two companies—Genentech and Vertex Pharmaceuticals—will bring insights about their work in genetic and genomic testing to the Exhibit Hall floor.

At Genentech, in Booths 6, 827, 1627, and 1827, respiratory science is in its DNA. For decades, the company has been researching serious and life-threatening lung diseases—making small steps every day that lead to breakthroughs for physicians and individuals with these diseases.

Genentech, which is celebrating its 40th anniversary this year, is focused on expanding its portfolio of respiratory medicines, which include:

  • Pulmozyme, approved in 1993 for children and adults with cystic fibrosis and still an essential treatment for CF
  • Xolair, approved in 2003 as the first and only biologic treatment for people older than 12 with moderate to severe persistent, uncontrolled allergic asthma
  • Esbriet, one of the first treatments for idiopathic pulmonary fibrosis

Looking ahead, Genentech is developing:

  • Lebrikizumab, designed to treat some of the nearly 15 million people suffering from severe asthma, the treatment is also being studied in idiopathic pulmonary fibrosis and chronic obstructive pulmonary disease
  • AMG 282, to be evaluated for the treatment of asthma and chronic obstructive pulmonary disease
  • Erivedge, a basal cell carcinoma treatment being evaluated in combination with Esbriet for the treatment of IPF

Genentech is excited to celebrate its rich heritage with the scientific community at ATS 2016.

Vertex Pharmaceuticals, in Booth 327, will showcase its growing understanding of how molecular defects in the cystic fibrosis transmembrane conductance regulator gene relate to the complex and varied clinical manifestations of CF.

This educational booth walks visitors through the mechanism of action of CFTR protein channels; the varied molecular consequences of CFTR mutations and resulting clinical phenotype; CFTR protein defects and their effect on total CFTR activity; CF pulmonary disease, immune response and lung microbiome interactions; and the microbial ecology of the lung and extrapulmonary clinical manifestations of CF.

Download the CF GeneE App on iTunes and have CFTR mutation information right at your fingertips.

Return to index page.